Skip to main content

Articles

Page 5 of 32

  1. Aβ42/Aβ40 ratios in cerebrospinal fluid (CSF) and blood are reduced in preclinical Alzheimer’s disease (AD), but their temporal and correlative relationship with cerebral Aβ pathology at this early disease sta...

    Authors: Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2023 15:64
  2. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:63

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  3. Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disea...

    Authors: Shreyasee Das, Julie Goossens, Dirk Jacobs, Nele Dewit, Yolande A. L. Pijnenburg, Sjors G. J. G. In ‘t Veld, Charlotte E. Teunissen and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:62
  4. Connectome mapping may reveal new treatment targets for patients with neurological and psychiatric diseases. However, the long-term delayed recall based-network with structural and functional connectome is sti...

    Authors: Jie Ma, Mou-Xiong Zheng, Jia-Jia Wu, Xiang-Xin Xing, Yun-Ting Xiang, Dong Wei, Xin Xue, Han Zhang, Xu-Yun Hua, Qi-Hao Guo and Jian-Guang Xu
    Citation: Alzheimer's Research & Therapy 2023 15:61
  5. Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...

    Authors: George Dranitsaris, Quanwu Zhang, Lin Mu, Christopher Weyrer, Erik Drysdale, Peter Neumann, Alireza Atri and Amir Abbas Tahami Monfared
    Citation: Alzheimer's Research & Therapy 2023 15:60
  6. Frontotemporal lobar degeneration (FTLD) is characterized pathologically by neuronal and glial inclusions of hyperphosphorylated tau or by neuronal cytoplasmic inclusions of TDP43. This study aimed at decipher...

    Authors: Claire Bridel, Juami H. M. van Gils, Suzanne S. M. Miedema, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, August B. Smit, Annemieke J. M. Rozemuller, Sanne Abeln and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2023 15:59
  7. Cortical and subcortical microstructural modifications are critical to understanding the pathogenic changes in frontotemporal lobar degeneration (FTLD) subtypes. In this study, we investigated cortical and sub...

    Authors: Wencai Ding, Peng Ren, Liye Yi, Yao Si, Fan Yang, Zhipeng Li, Hongbo Bao, Shi Yan, Xinyu Zhang, Siyang Li, Xia Liang and Lifen Yao
    Citation: Alzheimer's Research & Therapy 2023 15:58
  8. Midlife hypertension has been recognized as a modifiable risk factor for dementia, but association between blood pressure (BP) in late life and dementia has been inconclusive. In addition, few studies have inv...

    Authors: Mi Hee Cho, Kyungdo Han, Seungwoo Lee, Su-Min Jeong, Jung Eun Yoo, SangYun Kim, Jinkook Lee, Sohyun Chun and Dong Wook Shin
    Citation: Alzheimer's Research & Therapy 2023 15:56
  9. Insulin resistance (IR) and type 2 diabetes have been found to increase the risk for Alzheimer’s clinical syndrome in epidemiologic studies but have not been associated with tau tangles in neuropathological re...

    Authors: Gilda E. Ennis, Tobey J. Betthauser, Rebecca Langhough Koscik, Nathaniel A. Chin, Bradley T. Christian, Sanjay Asthana, Sterling C. Johnson and Barbara B. Bendlin
    Citation: Alzheimer's Research & Therapy 2023 15:55
  10. The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and d...

    Authors: Jagan A. Pillai, James Bena, Lynn Bekris, Nandan Kodur, Takhar Kasumov, James B. Leverenz and Sangeeta R. Kashyap
    Citation: Alzheimer's Research & Therapy 2023 15:54
  11. Alzheimer’s disease (AD) and osteoporosis are two distinct diseases but often occur in the same patient. Their relationship remains poorly understood. Studies using Tg2576 AD animal model demonstrate bone defi...

    Authors: Li Chen, Lei Xiong, Lingling Yao, Jinxiu Pan, Emily Arzola, Xiaojuan Zhu, Lin Mei and Wen-Cheng Xiong
    Citation: Alzheimer's Research & Therapy 2023 15:53
  12. A key histopathological hallmark of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles of aggregated microtubule-associated protein tau in neurons. Anle138b is a small molecule which has previ...

    Authors: Layla Hosseini-Gerami, Elena Ficulle, Neil Humphryes-Kirilov, David C. Airey, James Scherschel, Sarubini Kananathan, Brian J. Eastwood, Suchira Bose, David A. Collier, Emma Laing, David Evans, Howard Broughton and Andreas Bender
    Citation: Alzheimer's Research & Therapy 2023 15:52
  13. CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in bloodbrain barrier (BBB) leakage at dif...

    Authors: Xinyi Lv, Mengguo Zhang, Zhaozhao Cheng, Qiong Wang, Peng Wang, Qiang Xie, Ming Ni, Yong Shen, Qiqiang Tang and Feng Gao
    Citation: Alzheimer's Research & Therapy 2023 15:51
  14. The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo durin...

    Authors: Nils Heinzinger, Anne Maass, David Berron, Renat Yakupov, Oliver Peters, Jochen Fiebach, Kersten Villringer, Lukas Preis, Josef Priller, Eike Jacob Spruth, Slawek Altenstein, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Claudia Bartels, Frank Jessen…
    Citation: Alzheimer's Research & Therapy 2023 15:50
  15. Disease-modifying agents to counteract cognitive impairment in older age remain elusive. Hence, identifying modifiable factors promoting resilience, as the capacity of the brain to maintain cognition and funct...

    Authors: Kilian Abellaneda-Pérez, Gabriele Cattaneo, María Cabello-Toscano, Javier Solana-Sánchez, Lídia Mulet-Pons, Lídia Vaqué-Alcázar, Ruben Perellón-Alfonso, Cristina Solé-Padullés, Núria Bargalló, Josep M. Tormos, Alvaro Pascual-Leone and David Bartrés-Faz
    Citation: Alzheimer's Research & Therapy 2023 15:49
  16. Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully refle...

    Authors: Juan Lantero-Rodriguez, Agathe Vrillon, Aida Fernández-Lebrero, Paula Ortiz-Romero, Anniina Snellman, Laia Montoliu-Gaya, Wagner S. Brum, Emmanuel Cognat, Julien Dumurgier, Albert Puig-Pijoan, Irene Navalpotro-Gómez, Greta García-Escobar, Thomas K. Karikari, Eugeen Vanmechelen, Nicholas J. Ashton, Henrik Zetterberg…
    Citation: Alzheimer's Research & Therapy 2023 15:48
  17. Although a variety of brain lesions may contribute to the pathological assessment of dementia, the relationship of these lesions to dementia, how they interact and how to quantify them remains uncertain. Syste...

    Authors: Mohammed D. Rajab, Emmanuel Jammeh, Teruka Taketa, Carol Brayne, Fiona E. Matthews, Li Su, Paul G. Ince, Stephen B. Wharton and Dennis Wang
    Citation: Alzheimer's Research & Therapy 2023 15:47
  18. Restless leg syndrome (RLS) is associated with poor sleep quality, depression or anxiety, poor dietary patterns, microvasculopathy, and hypoxia, all of which are known risk factors for dementia. However, the r...

    Authors: Keun You Kim, Eun Hwa Kim, Myeongjee Lee, Junghee Ha, Inkyung Jung and Eosu Kim
    Citation: Alzheimer's Research & Therapy 2023 15:46
  19. There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer’s disease (AD). The ...

    Authors: Angelika Caputo, Amy Racine, Ines Paule, Pierre N. Tariot, Jessica B. Langbaum, Neva Coello, Marie-Emmanuelle Riviere, J. Michael Ryan, Cristina Lopez Lopez and Ana Graf
    Citation: Alzheimer's Research & Therapy 2023 15:45
  20. Neurofilament light (NfL) and neurogranin (Ng) are promising candidate AD biomarkers, reflecting axonal and synaptic damage, respectively. Since there is a need to understand the synaptic and axonal damage in ...

    Authors: Maya Arvidsson Rådestig, Ingmar Skoog, Tobias Skillbäck, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Ulf Andreasson, Hanna Wetterberg, Silke Kern and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2023 15:44
  21. In preclinical Alzheimer’s disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we...

    Authors: Zerrin Yildirim, Firuze Delen, David Berron, Hannah Baumeister, Gabriel Ziegler, Hartmut Schütze, Wenzel Glanz, Laura Dobisch, Oliver Peters, Silka Dawn Freiesleben, Luisa-Sophie Schneider, Josef Priller, Eike Jakob Spruth, Anja Schneider, Klaus Fliessbach, Jens Wiltfang…
    Citation: Alzheimer's Research & Therapy 2023 15:43
  22. Amyloid deposition is a primary predictor of Alzheimer’s disease (AD) and related neurodegenerative disorders. Retinal changes involving the structure and function of the ganglion cell layer are increasingly d...

    Authors: Daniel C. Javitt, Antigona Martinez, Pejman Sehatpour, Anna Beloborodova, Christian Habeck, Yunglin Gazes, Dalton Bermudez, Qolamreza R. Razlighi, D. P. Devanand and Yaakov Stern
    Citation: Alzheimer's Research & Therapy 2023 15:42
  23. There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer’s disease (AD). In this work, a temporal lobe composite () volume of interest (VOI) was evaluated in a longitudinal f...

    Authors: Vikas Kotari, Sudeepti Southekal, Michael Navitsky, Ian A. Kennedy, Ming Lu, Amanda Morris, Jennifer Ann Zimmer, Adam S. Fleisher, Mark A. Mintun, Michael D. Devous Sr and Michael J. Pontecorvo
    Citation: Alzheimer's Research & Therapy 2023 15:41
  24. Neuropsychology and imaging changes have been reported in the preclinical stage of familial Alzheimer’s disease (FAD). This study investigated the effects of APOEε4 and known pathogenic gene mutation on different...

    Authors: Meina Quan, Qi Wang, Wei Qin, Wei Wang, Fangyu Li, Tan Zhao, Tingting Li, Qiongqiong Qiu, Shuman Cao, Shiyuan Wang, Yan Wang, Hongmei Jin, Aihong Zhou, Jiliang Fang, Longfei Jia and Jianping Jia
    Citation: Alzheimer's Research & Therapy 2023 15:40
  25. Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesteras...

    Authors: Bruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine and Magda Tsolaki
    Citation: Alzheimer's Research & Therapy 2023 15:39

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:85

  26. Identifying blood-based signatures of brain health and preclinical pathology may offer insights into early disease mechanisms and highlight avenues for intervention. Here, we systematically profiled associatio...

    Authors: Rebecca E. Green, Jodie Lord, Marzia A. Scelsi, Jin Xu, Andrew Wong, Sarah Naomi-James, Alex Handy, Lachlan Gilchrist, Dylan M. Williams, Thomas D. Parker, Christopher A. Lane, Ian B. Malone, David M. Cash, Carole H. Sudre, William Coath, David L. Thomas…
    Citation: Alzheimer's Research & Therapy 2023 15:38
  27. Subtypes and patterns are defined using tau-PET (tau pathology) and structural MRI (atrophy) in Alzheimer’s disease (AD). However, the relationship between tau pathology and atrophy across these subtypes/patte...

    Authors: Rosaleena Mohanty, Daniel Ferreira, Agneta Nordberg and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:37

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:80

  28. Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in cl...

    Authors: Christophe Hirtz, Germain U. Busto, Karim Bennys, Jana Kindermans, Sophie Navucet, Laurent Tiers, Simone Lista, Jérôme Vialaret, Laure-Anne Gutierrez, Yves Dauvilliers, Claudine Berr, Sylvain Lehmann and Audrey Gabelle
    Citation: Alzheimer's Research & Therapy 2023 15:34
  29. Toll-like receptor 3 (TLR3) plays an important role in the immune/inflammatory response in the nervous system and is a main pathological feature of Alzheimer’s disease (AD). This study investigates the role of...

    Authors: Shang Wang, Taiyang Zhu, Wanyan Ni, Chao Zhou, Hui Zhou, Li Lin, Yuting Hu, Xiaoyu Sun, Jingjing Han, Yan Zhou, Guoliang Jin, Jie Zu, Hongjuan Shi, Xingxing Yang, Zuohui Zhang and Fang Hua
    Citation: Alzheimer's Research & Therapy 2023 15:33
  30. Electroencephalogram (EEG) has emerged as a non-invasive tool to detect the aberrant neuronal activity related to different stages of Alzheimer’s disease (AD). However, the effectiveness of EEG in the precise ...

    Authors: Bin Jiao, Rihui Li, Hui Zhou, Kunqiang Qing, Hui Liu, Hefu Pan, Yanqin Lei, Wenjin Fu, Xiaoan Wang, Xuewen Xiao, Xixi Liu, Qijie Yang, Xinxin Liao, Yafang Zhou, Liangjuan Fang, Yanbin Dong…
    Citation: Alzheimer's Research & Therapy 2023 15:32
  31. Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performan...

    Authors: Yu Guo, Xue-Ning Shen, Hui-Fu Wang, Shi-Dong Chen, Ya-Ru Zhang, Shu-Fen Chen, Mei Cui, Wei Cheng, Qiang Dong, Tao Ma and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:31
  32. To better assist with the design of future clinical trials for Alzheimer’s disease (AD) and aid in our understanding of the disease’s symptomatology, it is essential to clarify what roles β-amyloid (Aβ) plaque...

    Authors: Yue Cai, Jing Du, Anqi Li, Yalin Zhu, Linsen Xu, Kun Sun, Shaohua Ma and Tengfei Guo
    Citation: Alzheimer's Research & Therapy 2023 15:30
  33. Authors: Ignacio Illán-Gala, Victor Montal, Sergi Borrego-Écija, Maria Luisa Mandelli, Neus Falgàs, Ariane E. Welch, Jordi Pegueroles, Miguel Santos-Santos, Alexandre Bejanin, Daniel Alcolea, Oriol Dols-Icardo, Olivia Belbin, Mª. Belén Sánchez-Saudinós, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó…
    Citation: Alzheimer's Research & Therapy 2023 15:29

    The original article was published in Alzheimer's Research & Therapy 2022 14:27

  34. Mild cognitive impairment (MCI) has been thought of as the transitional stage between normal ageing and Alzheimer’s disease, involving substantial changes in brain grey matter structures. As most previous stud...

    Authors: Mingxi Dang, Caishui Yang, Kewei Chen, Peng Lu, He Li and Zhanjun Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:27
  35. To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or heredit...

    Authors: Marc Vervuurt, Anna M. de Kort, Lieke Jäkel, Iris Kersten, Wilson F. Abdo, Floris H. B. M. Schreuder, Ingeborg Rasing, Gisela M. Terwindt, Marieke J. H. Wermer, Steven M. Greenberg, Catharina J. M. Klijn, H. Bea Kuiperij and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2023 15:26
  36. Alzheimer’s disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated wi...

    Authors: Sterling C. Johnson, Marc Suárez-Calvet, Ivonne Suridjan, Carolina Minguillón, Juan Domingo Gispert, Erin Jonaitis, Agata Michna, Margherita Carboni, Tobias Bittner, Christina Rabe, Gwendlyn Kollmorgen, Henrik Zetterberg and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2023 15:25
  37. This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of cognitive impairment associated with probable Alzheim...

    Authors: Glen Wunderlich, Zuzana Blahova, Miguel Garcia and Frank Jessen
    Citation: Alzheimer's Research & Therapy 2023 15:24
  38. Alzheimer’s disease (AD) is an incurable neurodegenerative disorder characterised by the progressive buildup of toxic amyloid-beta (Aβ) and tau protein aggregates eventually leading to cognitive decline. Recen...

    Authors: Inès R. H. Ben-Nejma, Aneta J. Keliris, Verdi Vanreusel, Peter Ponsaerts, Annemie Van der Linden and Georgios A. Keliris
    Citation: Alzheimer's Research & Therapy 2023 15:23
  39. Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD). On the other hand, the apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor fo...

    Authors: Jaisalmer de Frutos Lucas, Kelsey R. Sewell, Alejandra García-Colomo, Shaun Markovic, Kirk I. Erickson and Belinda M. Brown
    Citation: Alzheimer's Research & Therapy 2023 15:22
  40. Dementia [i.e., Alzheimer disease (AD)], the most common neurodegenerative disease, causes profound negative impacts on executive function and quality of life. Available pharmacological treatments often fail t...

    Authors: Ping-Tao Tseng, Yen-Wen Chen, Bing-Yan Zeng, Bing-Syuan Zeng, Chao-Ming Hung, Cheuk-Kwan Sun, Yu-Shian Cheng, Brendon Stubbs, Andre F. Carvalho, Andre R. Brunoni, Kuan-Pin Su, Yu-Kang Tu, Yi-Cheng Wu, Tien-Yu Chen, Pao-Yen Lin, Chih-Sung Liang…
    Citation: Alzheimer's Research & Therapy 2023 15:20
  41. The earliest pathological features of Alzheimer’s disease (AD) appear decades before the clinical symptoms. The pathology affects the brain and the eye, leading to retinal structural changes and functional vis...

    Authors: Inés López-Cuenca, Alberto Nebreda, Alejandra García-Colomo, Elena Salobrar-García, Jaisalmer de Frutos-Lucas, Ricardo Bruña, Ana I. Ramírez, Federico Ramirez-Toraño, Juan J. Salazar, Ana Barabash, Pedro Gil, Fernando Maestú, José M. Ramírez and Rosa de Hoz
    Citation: Alzheimer's Research & Therapy 2023 15:19
  42. Neuroinflammatory factors, especially chemokines, have been widely reported to be involved in the pathogenesis of Alzheimer’s disease (AD). It is unclear how chemokines are altered in AD, and whether dysregula...

    Authors: Xiao Li, Deng-Feng Zhang, Rui Bi, Li-Wen Tan, Xiaogang Chen, Min Xu and Yong-Gang Yao
    Citation: Alzheimer's Research & Therapy 2023 15:17
  43. Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain. Of special interest is the effect of cerebral am...

    Authors: Susan Barendrecht, An Schreurs, Stefanie Geissler, Victor Sabanov, Victoria Ilse, Vera Rieckmann, Rico Eichentopf, Anja Künemund, Benjamin Hietel, Sebastian Wussow, Katrin Hoffmann, Kerstin Körber-Ferl, Ravi Pandey, Gregory W. Carter, Hans-Ulrich Demuth, Max Holzer…
    Citation: Alzheimer's Research & Therapy 2023 15:16
  44. Atrial fibrillation (AF) is a strong risk factor for Alzheimer’s disease (AD) independent of ischemic stroke. However, the clinicopathological impact of AF on the severity of AD has not been well elucidated. W...

    Authors: Taizen Nakase, Yasuko Tatewaki, Benjamin Thyreau, Hayato Odagiri, Naoki Tomita, Shuzo Yamamoto, Yumi Takano, Michiho Muranaka and Yasuyuki Taki
    Citation: Alzheimer's Research & Therapy 2023 15:15